Revelation Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
08/11/2024 21:50
* Revelation Biosciences Inc REVB.OQ reported a quarterly
adjusted loss of 84 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-12.60. The mean expectation of
two analysts for the quarter was for a loss of $2.84 per share.
Wall Street expected results to range from $-4.73 to -95 cents
per share.
* Reported revenue was zero; analysts expected zero.
* Revelation Biosciences Inc's reported EPS for the quarter
was a
loss of 84 cents.
* The company reported a quarterly loss of $2.24 million.
* Revelation Biosciences Inc shares had fallen by 0.2% this
quarter and lost 94.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 36.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Revelation
Biosciences Inc is $14.45
This summary was machine generated from LSEG data November 8 at
09:50 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -2.84 -0.84 Beat
Jun. 30 2024 -5.13
Mar. 31 2024 -5.38 -2.46 Beat
Dec. 31 2023 -13.77 -8.33 Beat